Advertisement


News

Once-Daily Tenofovir Alafenamide Appears Sufficient When Dosed With Rifampicin

March 6, 2018

Plasma concentrations of tenofovir alafenamide AUC were decreased by 55% and intracellular tenofovir-diphosphate concentrations by 36% when given with rifampicin. But intracellular concentrations were still 76% higher than those with standard dose tenofovir disoproxil fumarate.1

These data from RIFT, a pharmacokinetic (PK) study of once-daily tenofovir alafenamide (TAF) with rifampicin (RIF) conducted by Maddalena Cerrone and colleagues from Chelsea and Westminster Hospital, London, UK, The Johns Hopkins University, Baltimore, MD, USA, University of Liverpool, Liverpool, UK, University of Cape Town, Cape Town, South Africa, were presented at CROI 2018.
 The study is the first to measure PK of once-daily TAF with RIF and compare it directly to tenofovir disoproxil fumarate (TDF).

TAF achieves lower plasma and higher intracellular tenofovir (TFV) concentrations than TDF, but it is a substrate of drug transporters so has potential for drug interactions, especially with inducers like RIF.

Advertisement

A recent parallel design PK study showed when twice-daily TAF was given with RIF intracellular TFV-diphosphate (DP) decreased by 24% and plasma TAF by 15% compared with once-daily TAF alone.3,4

RIFT is a phase 1, open label, single arm, single centre evaluation in 23 HIV negative participants (21 completed). Participants received TAF/ FTC 25/200mg once daily (28 days) with food, followed by TAF/FTC + RIF 600mg once daily (28 days, RIF on empty stomach followed by TAF/
FTC with meal after 30 mins), followed by TDF 300mg once daily (28 days) with food.

The investigators performed intensive PK sampling on days 28 (TAF/FTC), 56 (TAF/FTC+RIF) and
 84 (TDF). Plasma TAF, TFV, FTC and intracellular TFV-DP and FTC-triphosphate (FTC-TP) concentrations were measured by validated LC-MS methods.

Participants were genotyped for polymorphisms.

Twenty-one participants completed all PK phases. Geometric mean ratios (GMR) for the main PK parameters are shown in Table 1.


Table 1: PK Once-Daily TAF + RIF vs TAF vs TDF
PK Parameter TAF + RIF vs TAF
GMR (90% CI)
TAF + RIF vs TDF
GMR (90% CI)
Plasma TAF
Cmax ng/mL CV 0.50 (0.42-0.61)  
AUC0-24 ng*h/mL CV 0.45 (0.33-0.60)  
Plasma TFV
Cmax ng/mL CV 0.35 (0.30-0.42)  
AUC0-24 ng*h/mL CV 0.46 (0.40-0.52)  
C24h fmol*h/106 CV 0.45 (0.42-0.50)  
Intracellular TFV-DP
Cmax ng/mL CV 0.62 (0.52-0.74) 0.23 (0.17-0.30)
AUC0-24 ng*h/mL CV 0.64 (0.54-0.75) 0.24 (0.18-0.32)
C24h fmol*h/106 CV 0.57 (0.47-0.71) 0.24 (0.18-0.32)


FTC-TP PK parameters were not affected by RIF. 
There were no significant associations with any polymorphisms.

There were two grade 3 adverse events and 2/23 participants discontinued: one case of transient hyper transaminitis during administration of TAF/FTC only (the investigators judged this to be unlikely drug related); one gastrointestinal symptoms (judged likely RIF-related).

The investigators concluded that although RIF co-administration decreased the plasma TAF by 55% and intracellular TFV-DP AUC by 36%, intracellular TFV-DP AUC were 76% higher with TAF + RIF than with TDF (300 mg once daily) alone.


Comment

These data support further evaluation of TAF + RIF in people with HIV and TB.

Unlike the previous TAF + RIF PK study, because of the comparison of intracellular TFV-DP concentrations with TAF + RIF to those with TDF alone, this evaluation suggests that doubling dose of TAF when coadministered with RIF is unnecessary.


References

  1. Cerrone M et al. Rifampin effect on tenofovir alafenamide (TAF) plasma/ intracellular pharmacokinetics. 25th CROI. Boston. 4-7 March 2018.
 Oral abstract 28LB.
  2. Custodio JM et al. Twice daily administration of tenofovir alafenamide in combination with rifampin: potential for tenofovir alafenamide use in HIV-TB coinfection. 16th European AIDS Conference (EACS). October 25-27 2017. Milan.  Oral abstract PS13/4.
  3. Clayden P. Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin. HTB. 28 November 2017.
    http://i-base.info/htb/32909

[Note from TheBodyPRO: This article was originally published by HIV i-Base on March 5, 2018. We have cross-posted it with their permission.]


Related Stories

HIV Research Highlights From First Day of CROI 2018



This article was provided by HIV i-Base. It is a part of the publication The 25th Conference on Retroviruses and Opportunistic Infections. Visit HIV i-Base's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.